Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry
Emilio J. Laserna‐Mendieta,Pilar Navarro,Sergio Casabona‐Francés,Edoardo V. Savarino,Edurne Amorena,Isabel Pérez‐Martínez,Danila Guagnozzi,Leonardo Blas‐Jhon,Elena Betoré,Antonio Guardiola‐Arévalo,Gaia Pellegatta,Anne Lund Krarup,Antonia Perello,Jesús Barrio,Carolina Gutiérrez‐Junquera,Carlos Teruel Sánchez‐Vegazo,Sonia Fernández‐Fernández,Juan Enrique Naves,Salvatore Oliva,Juan Armando Rodríguez‐Oballe,Silvia Carrión,Silvia Espina,Mónica Llorente Barrio,Maria Lluisa Masiques‐Mas,Raffaella Dainese,Sara Feo‐Ortega,Verónica Martín‐Dominguez,Jennifer Fernández‐Pacheco,Maria Teresa Pérez‐Fernández,Matteo Ghisa,Daria Maniero,Óscar Nantes‐Castillejo,Julia Nicolay‐Maneru,Adolfo Suárez,Iván Maray,Ronald Llerena‐Castro,Adriana Ortega‐Larrodé,Javier Alcedo,Alicia Granja Navacerrada,Francesca Racca,Cecilio Santander,Ángel Arias,Alfredo J. Lucendo,
DOI: https://doi.org/10.1002/ueg2.12533
2024-01-29
United European Gastroenterology Journal
Abstract:Abstract Background Swallowed topical corticosteroids (tC) are common therapy for patients with eosinophilic esophagitis (EoE). Widely heterogeneous results have occurred due to their active ingredients, formulations and doses. Objective To assess the effectiveness of topical corticosteroid therapy for EoE in real‐world practice. Methods Cross‐sectional study analysis of the multicentre EoE CONNECT registry. Clinical remission was defined as a decrease of ≥50% in dysphagia symptom scores; histological remission was defined as a peak eosinophil count below 15 per high‐power field. The effectiveness in achieving clinico‐histological remission (CHR) was compared for the main tC formulations. Results Overall, data on 1456 prescriptions of tC in monotherapy used in 866 individual patients were assessed. Of those, 904 prescriptions with data on formulation were employed for the induction of remission; 234 reduced a previously effective dose for maintenance. Fluticasone propionate formulations dominated the first‐line treatment, while budesonide was more common in later therapies. A swallowed nasal drop suspension was the most common formulation of fluticasone propionate. Doses ≥0.8 mg/day provided a 65% CHR rate and were superior to lower doses. Oral viscous solution prepared by a pharmacist was the most common prescription of budesonide; 4 mg/day provided no benefit over 2 mg/day (CHR rated being 72% and 80%, respectively). A multivariate analysis revealed budesonide orodispersible tablets as the most effective therapy (OR 18.9, p < 0.001); use of higher doses (OR 4.3, p = 0.03) and lower symptom scores (OR 0.9, p = 0.01) were also determinants of effectiveness. Conclusion Reduced symptom severity, use of high doses, and use of budesonide orodispersible tablets particularly were all independent predictors of tC effectiveness.
gastroenterology & hepatology